<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659799</url>
  </required_header>
  <id_info>
    <org_study_id>FiAsp-Exercise</org_study_id>
    <nct_id>NCT03659799</nct_id>
  </id_info>
  <brief_title>Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes</brief_title>
  <official_title>A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycemia is the main barrier for physical activity practice of patients with type 1
      diabetes (T1D). For postprandial exercise, anticipation with meal insulin bolus reduction is
      the recommended method to reduce exercise-associated hypoglycemic risk. The impact of faster
      acting Aspart (FiAsp) pharmacokinetic on hypoglycemic risk has not yet been explored. This
      study will explore two different timings for exercise onset.

      Objective: To compare the impact of rapid-acting insulin Aspart and faster acting Aspart
      (FiAsp) on glucose reduction during exercise.

      Design: This study is a randomized, four-way, crossover study to compare the efficacy of 1)
      rapid-acting insulin Aspart, and 2) FiAsp on glucose reduction during an exercise performed
      60 minutes or 120 minutes after breakfast. The insulin used and the timing of the exercise
      will be randomized. This project will be conducted at Institut de recherches cliniques de
      Montr√©al (IRCM, Montreal, Canada).

      Hypothesis: Faster acting Aspart (FiAsp) will be non-inferior to insulin Aspart for
      hypoglycemic risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in plasma glucose levels during exercise</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
    <description>Difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of the exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent below 4 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decremental area under the curve of plasma glucose levels</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels below 4 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an exercise-induced hypoglycemia below 3.9 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an exercise-induced hypoglycemia below 3.3 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring an oral treatment for hypoglycemia</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent above 10 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time (minutes) to the first hypoglycemic event</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of carbohydrates needed to treat a hypoglycemic event</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxyhemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in deoxyhemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total hemoglobin in the vastus lateralis</measure>
    <time_frame>60 minutes (exercise period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent below 4 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time of plasma glucose levels spent above 10 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels below 4 mmol/L</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring an oral treatment for hypoglycemia</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of carbohydrates needed to treat hypoglycemic events</measure>
    <time_frame>90 minutes after the end of exercise</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose levels</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hypoglycemia episodes requiring treatment</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of carbohydrates needed to treat hypoglycemic events</measure>
    <time_frame>4.5 hours (entire protocol period)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin FiAsp</intervention_name>
    <description>An insulin bolus of FiAsp will be given 5 minutes before breakfast</description>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>An insulin bolus of Aspart will be given 5 minutes before breakfast</description>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>60-minutes postprandial exercise</intervention_name>
    <description>A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast</description>
    <arm_group_label>Aspart - 60-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 60-minutes postprandial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>120-minutes postprandial exercise</intervention_name>
    <description>A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast</description>
    <arm_group_label>Aspart - 120-minutes postprandial exercise</arm_group_label>
    <arm_group_label>FiAsp - 120-minutes postprandial exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ‚â• 18 years of old.

          2. Clinical diagnosis of type 1 diabetes for at least one year.

          3. HbA1c ‚â§ 9.5%.

          4. Patients using multiple daily injections with basal-bolus insulin regimen and insulin
             analogs (pre-meal: Aspart, Lispro, Guilisine or Fiasp; basal: Detemir, Glargine U100 &amp;
             U300, Degludec U100).

          5. Written informed consent given.

        Exclusion Criteria:

          1. Clinically significant microvascular complications: nephropathy (estimated glomerular
             filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or
             severe proliferative retinopathy as judged by the investigator.

          2. Recent (&lt; 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac
             surgery.

          3. Anemia (Hb &lt; 100g/L).

          4. Ongoing pregnancy or breastfeeding.

          5. Severe hypoglycemic episode within two weeks of screening.

          6. Other serious medical illness likely to interfere with study participation or with the
             ability to complete the exercise periods by the judgment of the investigator (e.g.
             orthopedic limitation).

          7. Ongoing treatment with CSII (Continuous Subcutaneous Insulin Infusion) &quot;insulin pump
             therapy&quot;.

          8. Participation to a clinical trial in the last 3 months prior to inclusion in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Rabasa-Lhoret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montr√©al</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Supp√®re</last_name>
    <phone>514-987-5597</phone>
    <email>corinne.suppere@ircm.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montr√©al</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Supp√®re</last_name>
      <email>corinne.suppere@ircm.qc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

